The company displays sporadic revenue patterns, peaking at $7.9 million in 2025Q3 while maintaining high gross margins of 70.4% that appear to mask underlying operational volatility.
| Sales/Revenue | 14M | - | - |
| Revenue Growth % | - | - | - |
| Cost of Goods Sold | 0 | - | - |
| COGS % of Revenue | - | - | - |
| Gross Profit | 9.64M | 7.54M | 0 |
| Gross Margin % | 68.9% | 66.48% | - |
| Gross Profit Growth % | - | - | - |
| Operating Expenses | 3.38M | 2M | 309.02K |
| OpEx % of Revenue | - | 17.64% | - |
| Selling, General & Admin | 3.34M | 1.99M | 309.02K |
| SG&A % of Revenue | - | 17.58% | - |
| Research & Development | 0 | - | - |
| R&D % of Revenue | - | - | - |
| Other Operating Expenses | 0 | - | - |
| Operating Income | 6.26M | 5.54M | -309.02K |
| Operating Margin % | 44.74% | 48.84% | - |
| Operating Income Growth % | - | 1893.39% | - |
| EBITDA | 7.85M | 5.74M | -309.02K |
| EBITDA Margin % | 56.1% | 50.56% | - |
| EBITDA Growth % | - | 1956.37% | - |
| D&A (Non-Cash Add-back) | 83.58K | 194.6K | 0 |
| EBIT | 7.77M | 5.54M | -309.02K |
| Net Interest Income | 1.68M | 53.49K | 0 |
| Interest Income | 1.68M | 53.49K | 0 |
| Interest Expense | 0 | 0 | 0 |
| Other Income/Expense | 0 | - | - |
| Pretax Income | 7.96M | 5.61M | -309.02K |
| Pretax Margin % | 56.84% | 49.43% | - |
| Income Tax | 2.52M | 1.61M | -226 |
| Effective Tax Rate % | 31.67% | 28.76% | 0.07% |
| Net Income | 5.44M | 4M | -308.79K |
| Net Margin % | 38.84% | 35.22% | - |
| Net Income Growth % | - | 1394.08% | - |
| Net Income (Continuing) | 5.44M | 4M | -308.79K |
| Discontinued Operations | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| EPS (Diluted) | 0.11 | 0.08 | -0.03 |
| EPS Growth % | - | 324.78% | - |
| EPS (Basic) | - | 0.08 | -0.03 |
| Diluted Shares Outstanding | 47.69M | 51.23M | 8.9M |
| Basic Shares Outstanding | 47.69M | 51.23M | 8.9M |
| Dividend Payout Ratio | - | - | - |
Extreme Liquidity and Reporting Discrepancies
As reported in recent financial filings, the company exhibits highly intermittent revenue generation, with quarterly figures fluctuating between zero and $7.9 million, suggesting that the business model may rely on lumpy, project-based contracts rather than a consistent, recurring stream of consumer-facing biotech food product sales.
The absence of revenue in multiple quarters indicates a lack of operational consistency that complicates long-term forecasting. Investors should monitor whether these gaps represent genuine business pauses or potential issues with revenue recognition timing and contract fulfillment cycles.
Based on the provided income statement data, the company maintains robust gross margins, peaking at 70.4% in 2025Q3, which implies significant pricing power or a highly specialized product mix that effectively insulates the firm from standard commodity-level cost pressures within the functional food sector.
While these margins appear structurally attractive, they are only realized during periods of active revenue generation. The inability to maintain consistent gross profit suggests that the company's cost structure may be poorly optimized for periods of low activity, leading to significant operating margin swings.
According to the latest quarterly reports, the company demonstrates high operating leverage, as evidenced by the 58.0% operating margin achieved in 2025Q3, though this efficiency is entirely contingent upon the company's ability to sustain revenue levels above the threshold required to cover fixed SG&A expenses.
The firm's SG&A costs remain relatively persistent even when revenue drops to zero, which creates a high break-even point. This structure suggests that the company may struggle to maintain profitability during prolonged periods of market inactivity or supply chain disruption.
As indicated by the historical income statements, the company has reported positive net income in quarters where revenue was zero, such as 2024Q2 and 2024Q1, which warrants further investigation into the nature of non-operating items or potential accounting adjustments impacting the bottom line.
These instances of profitable quarters without corresponding top-line growth suggest that the reported net income may not be reflective of core operational performance. Analysts should be cautious of these anomalies, as they may obscure the underlying economic reality of the business's cash-generating capabilities.
Quick answers to the most common questions about buying UCFIW stock.
CN Healthy Food Tech Group Corp. (UCFIW) is profitable, generating $4.0M in net income for the fiscal year ending 2024 with a net profit margin of 35.2%.
CN Healthy Food Tech Group Corp. (UCFIW) reported an operating income of $5.5M, resulting in an operating profit margin of 48.8%. This margin reflects the operational efficiency of the business before interest and taxes.
CN Healthy Food Tech Group Corp. (UCFIW) generated $7.5M in gross profit for the year, representing a gross profit margin of 66.5%. This demonstrates the company's core pricing power and production efficiency.